AYTU Aytu Biopharma (AYTU) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001385818
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter
Aytu Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for AYTU BIOPHARMA, INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 56.6% of the 29,462 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Disbrow Jarrett bought about $25.0K of AYTU on Jun 9, 2025, the largest insider purchase at the company since 2023; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Feb 28, 2025.
- -21.9% median (-13.9% mean) 90-day return after 4 previous buys.
- The trade is 43.5% of the 153,257 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Disbrow Joshua R. bought about $100.0K of AYTU on Jun 9, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 14, 2023.
- -36.3% median (-32.5% mean) 90-day return after 3 previous buys.
- The trade is 17.3% of the 86,591 shares held after it.
- No other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Disbrow Joshua R. bought about $19.5K of AYTU on Feb 28, 2025, the largest insider purchase at the company since 2023; 15 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 19, 2022.
- The trade is 54.7% of the 21,935 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commerical Officer PYSZCZYMUKA GREG bought about $22.4K of AYTU on Jun 16, 2023; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 19, 2022.
- -45.0% median (-45.0% mean) 90-day return after 2 previous buys.
- The trade is 19.6% of the 71,591 shares held after it.
- 1 other insider bought within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Disbrow Joshua R. bought about $26.0K of AYTU on Jun 14, 2023; 1 other insider bought within 30 days and 15 funds added in the latest 13F quarter.11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
-13.3% year over year
below 67% of Pharma & Biotech
Margin
-24.8% net margin
more than 56% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.5% of the float short (float per yahoo 2026-10-26) · 4.7 days to cover · settled 2026-09-30
below 59% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AYTU
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-15.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AYTU: institutional holders (13F)
13F holdings, latest reported quarter
5,903,159 sh
$11.6M
2,173,624 sh
$4.7M
619,574 sh
$1.3M
261,146 sh
$561.5K
200,000 sh
$430.0K
Congress trades in AYTU
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AYTU planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AYTU mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Dimensional US Sustainability Core 1 ETF
$10.7K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$115.0K position · as of 2026-05-31
0.0%
Omni Small-Cap Value Fund
$3.2K position · as of 2026-06-30
0.0%
U.S. VECTOR EQUITY PORTFOLIO
$12.2K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$198.1K position · as of 2026-06-30
0.0%
U.S. Social Core Equity 2 Portfolio
$3.9K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 3
0 active
1
Phase 4
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Joshua R. Disbrow
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$844.9K
$854.8K
$553.2K
+34%
n/a
2024
$883.9K
$867.1K
$462.1K
+36%
n/a
2023
$928.2K
$919.2K
$547.7K
+82%
n/a
2022
$708.0K
$391.8K
$506.0K
-88%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AYTU financials
Revenue growth
-13.3%
XBRL, annual
Net margin
-24.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$57.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AYTU
| FY Jun 2026 | $57.6M |
| FY Jun 2025 | $66.4M |
| FY Jun 2024 | $81.0M |
| FY Jun 2023 | $107.4M |
| FY Jun 2022 | $96.7M |
| Jun 2026 | $16.1M |
| Mar 2026 | $12.4M |
| Dec 2025 | $15.2M |
| Sep 2025 | $13.9M |
| Jun 2025 | $15.1M |
| Mar 2025 | $18.5M |
| Dec 2024 | $16.2M |
| Sep 2024 | $16.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-24.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AYTU
| FY Jun 2026 | -24.8% |
| FY Jun 2025 | -20.5% |
| FY Jun 2024 | -19.5% |
| FY Jun 2023 | -15.9% |
| FY Jun 2022 | -112.5% |
| Jun 2026 | -0.4% |
| Mar 2026 | -45.3% |
| Dec 2025 | -69.8% |
| Sep 2025 | +14.1% |
| Jun 2025 | -131.2% |
| Mar 2025 | +21.6% |
| Dec 2024 | +4.9% |
| Sep 2024 | +8.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AYTU
| FY Jun 2026 | $3.3M |
| FY Jun 2025 | -$2.2M |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | $4.4M |
| Mar 2026 | -$4.2M |
| Dec 2025 | $3.7M |
| Sep 2025 | -$618.0K |
| Jun 2025 | $2.8M |
| Mar 2025 | -$6.5M |
| Dec 2024 | $2.9M |
| Sep 2024 | -$1.3M |
At each fiscal year end
Single quarter
Debt to equity
0.31x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AYTU
| FY Jun 2026 | 0.31x |
| FY Jun 2025 | 0.67x |
| FY Jun 2024 | 0.46x |
| FY Jun 2023 | 0.38x |
| FY Jun 2022 | 0.42x |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.32x |
| Dec 2025 | 0.83x |
| Sep 2025 | 0.53x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.33x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.30x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AYTU
| FY Jun 2026 | 0.30x |
| FY Jun 2025 | -0.15x |
| FY Jun 2024 | -0.11x |
| FY Jun 2023 | -0.35x |
| FY Jun 2022 | -1.53x |
| Jun 2026 | 0.30x |
| Mar 2026 | 0.15x |
| Dec 2025 | -0.05x |
| Sep 2025 | -0.11x |
| Jun 2025 | -0.15x |
| Mar 2025 | -0.49x |
| Dec 2024 | 0.06x |
| Sep 2024 | -0.19x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-52.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AYTU
| FY Jun 2026 | -52.7% |
| FY Jun 2025 | -58.3% |
| FY Jun 2024 | -47.1% |
| FY Jun 2023 | -40.8% |
| FY Jun 2022 | -119.6% |
| Jun 2026 | -52.7% |
| Mar 2026 | -97.4% |
| Dec 2025 | -108.9% |
| Sep 2025 | -49.5% |
| Jun 2025 | -58.3% |
| Mar 2025 | +5.1% |
| Dec 2024 | -16.3% |
| Sep 2024 | -20.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AYTU
| FY Jun 2026 | -12.5% |
| FY Jun 2025 | -11.2% |
| FY Jun 2024 | -12.4% |
| FY Jun 2023 | -12.4% |
| FY Jun 2022 | -53.9% |
| Jun 2026 | -12.5% |
| Mar 2026 | -28.9% |
| Dec 2025 | -20.6% |
| Sep 2025 | -10.9% |
| Jun 2025 | -11.2% |
| Mar 2025 | +1.3% |
| Dec 2024 | -4.2% |
| Sep 2024 | -5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AYTU
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -7.2% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-14.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AYTU
| FY Jun 2026 | -14.9% |
| FY Jun 2025 | -13.4% |
| FY Jun 2024 | -2.6% |
| FY Jun 2023 | -24.3% |
| FY Jun 2022 | n/a |
| Jun 2026 | -14.9% |
| Mar 2026 | -28.8% |
| Dec 2025 | -16.0% |
| Sep 2025 | -14.8% |
| Jun 2025 | -13.4% |
| Mar 2025 | -5.0% |
| Dec 2024 | -10.9% |
| Sep 2024 | -2.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing AYTU
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.6M
market value at close 2026-10-26 on 2026-09-15 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AYTU
| FY Jun 2026 | $7.7M |
| FY Jun 2025 | -$4.7M |
| FY Jun 2024 | $9.0M |
| FY Jun 2023 | -$2.1M |
| FY Jun 2022 | $531.8M |
| Jun 2026 | $7.7M |
| Mar 2026 | $14.0M |
| Dec 2025 | $8.3M |
| Sep 2025 | -$1.7M |
| Jun 2025 | -$4.7M |
| Mar 2025 | $622.8K |
| Dec 2024 | $1.9M |
| Sep 2024 | $6.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+15.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield AYTU
| FY Jun 2026 | +14.1% |
| FY Jun 2025 | -16.1% |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | +14.1% |
| Mar 2026 | +5.6% |
| Dec 2025 | -2.6% |
| Sep 2025 | -7.8% |
| Jun 2025 | -16.1% |
| Mar 2025 | -82.0% |
| Dec 2024 | +1.9% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing AYTU
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $81.0M | $107.4M |
| Gross profit | $36.8M | $45.8M | $49.1M | $66.6M |
| Operating income | -$8.3M | -$7.8M | -$1.6M | -$17.1M |
| Net income | -$14.3M | -$13.6M | -$15.8M | -$17.1M |
| EPS (diluted) | n/a | n/a | n/a | -5.11 |
| Operating cash flow | $3.3M | -$1.9M | -$1.4M | -$5.1M |
| Cash | $26.3M | $31.0M | $20.0M | $23.0M |
| Long-term debt | $9.1M | $10.9M | $10.9M | $14.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
AYTU Stock Sonar score 5/7 axes
Find similar shapesCompareAYTU ranks highest on risk and compliance (73rd percentile) and profitability (67th), and lowest on institutional and government (27th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
